Sign in
TerminatedPhase 1

Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary

Key facts

Who runs it
Abramson Cancer Center at Penn Medicine
Where
Philadelphia, United StatesSee the site
Trial code
Status
Terminated
Phase
Phase 1
People taking part
1 person enrolled
Started
26 Aug 2020
Ended
31 Jan 2024
Type of study
Interventional
Treatments tested
  • Nivolumab
  • Ipilimumab
  • bland embolization
Record updated
26 April 2024
Why it stopped
failure to accrue

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Metastatic renal cell carcinoma with unresected primary tumor or with metastasis amenable to embolization
  • No prior immune checkpoint therapy
  • Primary tumor or metastasis amenable to percutaneous embolization per review by the treating interventional oncologist; Patent feeding artery to tumor > 2 mm diameter without macroscopic arteriovenous fistula/shunt
  • Additional metastatic site > 1 cm assessable for response by RECIST 1.1
  • Adequate organ function by screening laboratory studies within 30 days of embolization; platelets > 50K, correctable by transfusion; INR < 1.5, correctable by transfusion; creatinine < 2.0
  • ECOG performance status 0-2
  • Age ≥ 18 years
  • Have signed the current approved informed consent form and be willing and able to comply with this protocol
  • Women of childbearing potential (WOCBP) must use appropriate method(s) of contraception. WOCBP should use an adequate method to avoid pregnancy for 5 months after the last dose of study drug
  • Women of childbearing potential must have a negative serum or urine pregnancy test
  • Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year Men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 7 months after the last dose

Who cannot take part

  • Glucocorticoid (> 10 mg daily prednisone equivalents) or immunosuppressant therapy
  • Autoimmune disorder; subjects are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment
  • Immunodeficiency syndrome
  • Active infection requiring systemic therapy
  • Any other medical or personal condition that, in the opinion of the site investigator, may potentially compromise the safety or compliance of the patient, or may preclude the patient's successful completion of the clinical trial
  • Positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection
  • Contrast allergy not mitigated by usual prophylaxis
  • Untreated CNS metastasis

Where in United States

  • Hospital of the University of PennsylvaniaPhiladelphia, United States

About the trial

What the trial wants to find out

This single center phase 1 trial will study the combination of nivolumab+ipilimumab with embolization in participants with renal cell carcinoma. The study will evaluate the safety of embolotherapy in patients with metastatic RCC receiving nivolumab+ipilimumab. The hypothesis is that the number of serious adverse events will be no greater than the number of serious adverse events for both therapies combined.

The group in the trial

  • Ipilimumab +Nivolumab with EmbolizationTreatment being tested

    Patients initiate ICI therapy with Nivolumab 3 mg/kg + ipilimumab 1/mg/kg IV every 3 weeks x 4 cycles, followed by nivolumab 480mg flat dose IV every four weeks for a total of 6 months of therapy unless stopped for confirmed progression or intolerable toxicities. Patients will receive 2 cycles of systemic therapy followed by embolization of their primary tumor or metastatic lesion(s) and continue systemic therapy subsequently.

    Treatment: Nivolumab, Ipilimumab, and bland embolization

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
UPCC06820 Phase 1 Trial of Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary
Record updated
26 April 2024